OECD TG 407
OECD TG 407, OECD Test Guidelines for the Testing of Chemicals, Section 4 (Health Effects) as part of the ‘28-day oral toxicity study with repeated administration in rodents’, i.e. the standard ‘28-day oral toxicity study with repeated administration in rodents’. It was first adopted in 1981, updated in 1995 and revised in 2008 to include endocrine-sensitive endpoints. The test is an in vivo toxicity study designed to evaluate the toxic effects, target organs and dose-response relationship of a substance following repeated oral administration over 28 days
The basic principle of the test is as follows:
- The test substance is usually administered to rats daily for 28 days, either by gavage or, if necessary, via their feed or drinking water.
- As a rule, three dose groups and a control group are used; the dose levels are determined on the basis of preliminary trials or existing data. A high dose should produce toxic effects, but should not result in a high mortality rate or excessive pain.
- As a rule, at least 10 animals (5 males + 5 females) are used in each group; additional animals may be included for blood and tissue analyses.
- The animals are clinically monitored on a daily basis; their body weight and feed and water intake are recorded regularly.
- At the end of the study, haematological tests, clinical chemistry tests and urine analyses will be carried out.
- The weights of the organs are measured and a macroscopic post-mortem examination is carried out.
- A histopathological examination of the major organs is carried out.
- The endocrine-sensitive endpoints added in the 2008 revision are assessed: Thyroid (T3, T4, TSH), testes and epididymis (sperm count, motility, morphology), oestrus cycle, histopathology of the ovaries, uterus and vagina.
The key parameters reported in the study are as follows:
- Dosages used (mg/kg/day) and route of administration
- Clinical observations and their onset
- Changes in body weight and feed/water intake
- Haematological parameters (complete blood count, white blood cell differential, etc.)
- Clinical chemistry parameters (liver and kidney function tests, electrolytes, glucose, lipids, etc.)
- Results of the urine analysis
- Organ weights (absolute and relative)
- Macroscopic post-mortem findings
- Histopathological findings (target organs and endocrine organs)
- Endocrine-sensitive endpoints (hormone levels, sperm parameters, oestrus cycle)
- NOAEL/LOAEL values and dose-response relationship
- Data on measurement uncertainty and repeatability
Why is it carried out?
OECD TG 407 is being carried out for the following scientific and regulatory purposes:
- Characterisation of toxicity following repeated administration: identification of systemic toxic effects and target organs following 28 days of repeated oral exposure
- Assessment of the dose-response relationship: determination of the NOAEL and LOAEL values
- Assessment of target organ toxicity: evaluation of histopathological changes, particularly in the liver, kidneys, haematopoietic system, endocrine organs and reproductive organs
- Preliminary assessment of endocrine effects: screening for endocrine activity based on endpoints such as thyroid hormones, sperm parameters and the oestrous cycle
- Support with the preparation of authorisation dossiers: for use in safety assessments under REACH, for biocides, plant protection products, medicinal products and industrial chemicals
- Provision of preliminary data for long-term studies: as a basis for dose determination in 90-day studies (TG 408) or chronic studies
- Contribution to risk assessment: Provision of baseline data for risk assessment in scenarios involving repeated exposure
- Evidence-based approach: a contribution to the holistic assessment of the substance in conjunction with other toxicological, physicochemical and exposure data
OECD TG 407 does not provide any information on acute toxicity or carcinogenicity; these effects must be assessed in separate tests. The results should be interpreted taking into account the chemical structure of the substance, other toxicity data (e.g. TG 408, TG 422) and the exposure assessment.
As part of our nano-testing services, we conduct 28-day repeated-dose oral toxicity studies in accordance with OECD TG 407 with scientific rigour, utilising our accredited laboratory facilities and quality management system. Our scope of services includes the following:
- Preparation of a study protocol in accordance with OECD TG 407
- Scientific justification for the dose levels, based on the physicochemical properties of the test substance and the available toxicity data
- Selection of a suitable carrier (vehicle) and assessment of solubility and stability
- Determination of species, sex, age, route of administration and observation period
- Planning of the control and treatment groups, the number of animals and additional analysis groups
- Compliance with ethical approval and animal welfare requirements
Please feel free to contact Nano-Test for information on study design, dose determination, planning of endocrine-sensitive endpoints, sample collection conditions, the testing schedule and reporting procedures for your 28-day repeated-dose oral toxicity studies in accordance with OECD TG 407.

